Abstract Topics

Late Breaking Abstract Submission is Open

There are 4 ways to present at ESPID:

  1. In a parallel symposium
  2. As an oral presentation
  3. As an e-Poster (including chance to present it)
  4. A case for a Meet the Expert session

Find out the ESPID 2021 abstract topics below and start planning your abstract:

Symposium Topics

  • Infections in pediatric transplant medicine
  • Digital tools and machine learning for pediatric infectious diseases
  • Multidrug-resistant bacteria and the spread of antimicrobial resistance
  • Prevention of adhesion and invasion of Staphylococcus aureus (Young ESPID debate)
  • Prevention of SARS-CoV-2 transmission
  • Microbiology
  • The spread of antimicrobial resistance
  • Digitalisation and machine learning in clinical microbiology
  • Neonatal sepsis
  • Controlling arthropod tropical infections
  • New fronts for prevention of congenital CMV
  • COVID-19 clinical and treatment
  • Antibiotic treatment revisited
  • Modern approaches to diagnosing lung infections (Shared symposium with FIND)
  • Managing “trivial” infections  (Young ESPID)
  • Vaccines in the spotlight of pandemics
  • Controlling arthropod tropical infections
  • Cytomegalovirus
  • Pneumonia
  • Pediatric COIVD-19 clinical presentation and treatment
  • New developments in antibiotic treatment
  • TB and HIV
  • Novel diagnostics

Meet the Expert Topics

  • Congenital infections
  • Mycobacteria
  • Breastfeeding in HIV exposed children
  • Pediatric Infectious Diseases in refugee children
  • Meningitis/encephalitis
  • Tropical infectious diseases
  • Fever of Unknown Origin
  • PIMS-TS / MIS-C
  • Sepsis
  • Bone and joint infections
  • Infection and immune compromised host
  • Telemedicine for pediatric infectious diseases
  • Vaccine hesitancy and motivational interviewing
  • Multisystem inflammatory syndrome in children (MIS-C)

 

General Abstract Topics

  • Antimicrobials
    • Novel antimicrobial treatments 
    • Resistance 
    • Pharmacology
  • Public health and epidemiology (only non SARS-CoV2 content)
    • Population studies and surveillance
    • Modelling studies
  • Vaccines (only non SARS-CoV2 content)
    • Vaccine development (phase 1-2) –  viral
    • Vaccine development (phase 1-2)  – bacterial and all non-viral
    • Vaccine efficacy (phase 3) and effectiveness – viral
    • Vaccine efficacy (phase 3) and effectiveness – bacterial and all non-viral
    • Vaccine safety (post licensure)
    • Vaccine hesitancy
  • Immunology & compromised host
    • Host-pathogen interaction
    • Host response diagnostics and imaging
    • Severe/systemic fungal infections
    • Infections in immunocompromised patients
  • Global health
    • Zoonosis, vector-borne and emerging infections
    • Tropical/parasite infections & travel medicine
    • Refugees and migrants
  • Infections in early life
    • Congenital and perinatal infections
    • Neonatal sepsis
  • Non-respiratory infections
    • Gastrointestinal infections
    • Urogenital infections
    • CNS infections
    • Systemic and multi-organ infections
    • Skin Infections
  • Respiratory infections (only non-SARS-CoV2 content)
    • Viral respiratory infections 
    • Bacterial pneumonia
    • ENT infections
  • Mycobacteria and retroviruses
    •  Tuberculosis and other mycobacterial infections
    • HIV/AIDS
  • Digital tools and machine learning
    • Decision support tools 
    • Artificial intelligence in microbiology and radiology
    • Telemedicine
  •  Covid-19
    •  Epidemiology and risk factors
    • Clinical manifestations 
    • Diagnostics (Screening and testing)
    • Treatment
    • Prevention of transmission 
    • Vaccines
  • Microbiology
    • Near-patient, rapid testing
    • Novel diagnostics 
  • Other
Continue to Abstract Submission